NewEdge Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.81M Buy
12,759
+140
+1% +$22.5K 0.01% 1283
2026
Q2
$2.13M Sell
12,619
-447
-3% -$66.3K 0.01% 1182
2026
Q1
$1.72M Buy
13,066
+68
+0.5% +$9.02K 0.01% 1185
2025
Q4
$1.84M Buy
12,998
+672
+5% +$97.4K 0.01% 1115
2025
Q3
$1.73M Buy
12,326
+1,603
+15% +$217K 0.01% 1092
2025
Q2
$1.35M Buy
10,723
+3,093
+41% +$355K 0.01% 1125
2025
Q1
$844K Buy
7,630
+2,747
+56% +$348K 0.01% 1278
2024
Q4
$667K Sell
4,883
-169
-3% -$20.9K ﹤0.01% 1382
2024
Q3
$582K Buy
5,052
+1,959
+63% +$269K ﹤0.01% 1379
2024
Q2
$426K Buy
3,093
+213
+7% +$29.2K ﹤0.01% 1507
2024
Q1
$397K Buy
2,880
+2,428
+537% +$332K ﹤0.01% 1478
2023
Q4
$59.6K Buy
452
+404
+842% +$46.5K ﹤0.01% 2172
2023
Q3
$5.4K Hold
48
– – ﹤0.01% 2784
2023
Q2
$4.53K Sell
48
-413
-90% -$40.4K ﹤0.01% 2855
2023
Q1
$46.7K Sell
461
-13,474
-97% -$1.4M ﹤0.01% 2035
2022
Q4
$1.61M Buy
+13,935
New +$1.63M 0.04% 369

Other funds holding NBIX

NewEdge Advisors's NBIX Position: Q3 2026 in Review

NewEdge Advisors increased its Neurocrine Biosciences (NBIX) stake by 1.1% in Q3 2026, buying an estimated $22.5K and bringing the position to 12,759 shares worth $1.81M. The position accounts for 0.01% of the portfolio, ranked #1283.

NewEdge Advisors first reported a position in NBIX in Q4 2022 and has held it in 16 quarters since. The position peaked at $2.13M in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • NewEdge Advisors held 12,759 shares of Neurocrine Biosciences worth $1.81M as of Q3 2026.
  • NewEdge Advisors bought 140 Neurocrine Biosciences shares in Q3 2026, an estimated $22.5K.
  • Neurocrine Biosciences made up 0.01% of NewEdge Advisors's portfolio in Q3 2026, its #1283 holding.
  • NewEdge Advisors first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 16 quarters since.
  • NewEdge Advisors's Neurocrine Biosciences position peaked at $2.13M in Q2 2026.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.